Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TAKEDA-ABBOTT PREVACID FOR SHORT-TERM HEALING OF EROSIVE ESOPHAGITIS, SYMPTOM RELIEF FOR UP TO EIGHT WEEKS RECOMMENDED FOR APPROVAL BY FDA COMMITTEE

Executive Summary

Takeda-Abbott Pharmaceuticals' proton pump inhibitor Prevacid (lansoprazole) for short-term healing and symptomatic relief of up to eight weeks in duration for patients with grade 2 and higher acute erosive reflux esophagitis received a unanimous 9-0 recommendation for approval Dec. 2 from FDA's Gastrointestinal Drugs Advisory Committee.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025418

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel